NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026GlobeNewsWire • 03/03/26
NovaBridge to Present at the Leerink Partners 2026 Global Healthcare ConferenceGlobeNewsWire • 03/02/26
NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech PlatformGlobeNewsWire • 02/19/26
NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric CancerGlobeNewsWire • 02/17/26
NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric CancerGlobeNewsWire • 01/06/26
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IOGlobeNewsWire • 12/10/25
NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IOGlobeNewsWire • 12/04/25
NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 ForwardGlobeNewsWire • 11/21/25
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian CountriesGlobeNewsWire • 10/29/25
I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech PlatformGlobeNewsWire • 10/29/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMABPRNewsWire • 10/28/25
I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025GlobeNewsWire • 10/22/25
I-Mab (IMAB) Discusses Business Transformation Strategy and Plans for Accelerated Growth TranscriptSeeking Alpha • 10/17/25
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge BiosciencesGlobeNewsWire • 10/16/25
I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics ConferenceGlobeNewsWire • 10/14/25
I-Mab Sponsored ADR (IMAB) Is Up 24.14% in One Week: What You Should KnowZacks Investment Research • 10/10/25
Are You Looking for a Top Momentum Pick? Why I-Mab Sponsored ADR (IMAB) is a Great ChoiceZacks Investment Research • 08/28/25
I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development CommitteeGlobeNewsWire • 08/25/25
I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary SharesGlobeNewsWire • 08/01/25